Use Triumeq (abacavir, dolutegravir, and lamivudine) as ordered by your doctor. Main demographics and outcomes are summarised in Table 5. In rabbits, maternal toxicity (decreased food consumption, scant/no faeces/urine, suppressed body weight gain) was observed at 1000 mg/kg (0.74 times the 50 mg human clinical exposure when administered in combination with abacavir and lamivudine based on AUC).Lamivudine was not teratogenic in animal studies but there were indications of an increase in early embryonic deaths in rabbits at relatively low systemic exposures, comparable to those achieved in humans. • Never double-up the dose.
Patients should be informed that dizziness has been reported during treatment with dolutegravir. Dolutegravir is the predominant circulating compound in plasma; renal elimination of unchanged active substance is low (< 1% of the dose). The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir. All rights reserved. In 13 treatment-naïve subjects on a stable dolutegravir plus abacavir/lamivudine regimen, dolutegravir concentration in CSF averaged 18 ng/mL (comparable to unbound plasma concentration, and above the ICDolutegravir is present in the female and male genital tract. The proportion with a positive HCV serology was 7%. Elderly: There are limited data available on the use of dolutegravir, abacavir and …
Each pack of 30 film-coated tablets contains a desiccant.Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu Stockley Park West, Uxbridge, Middlesex,, UB11 1BT, UKTo bookmark a medicine you must sign up and log in.To view the changes to a medicine you must sign up and log in. They do not measure exact amounts.
However, if you do not remember until later, skip the missed dose … † Includes subjects who discontinued prior to Week 48 for lack or loss of efficacy and subjects who are ≥50 copies in the 48 week window. Triumeq is available as a purple film-coated tablet. In 100% human serum, the mean fold shift for dolutegravir activity was 75-fold, resulting in protein adjusted ICSerial passage is used to study resistance evolution In further selection experiments using clinical isolates of subtype B, mutation R263K was seen in all five isolates (after 20 weeks and onwards). Abacavir is also excreted into human milk.Based on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed infants of mothers treated for HIV are very low (< 4% of maternal serum concentrations) and progressively decrease to undetectable levels when breastfed infants reach 24 weeks of age.
Elderly Those reported in at least 10% of patients with a hypersensitivity reaction are in bold text.Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however reactions have occurred without rash or fever.
‡ Includes subjects who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 analysis window if this resulted in no virologic data on treatment during the analysis window. Triumeq may be used during the second and third trimester of pregnancy when the expected benefit justifies the potential risk to the foetus.Concerning lamivudine, a large amount of data (more than 5200 outcomes from first trimester) indicates no malformative toxicity. If overdose occurs, the patient should be treated supportively with appropriate monitoring, as necessary. Your doctor might prescribe … Reference should be made to treatment guidelines. Dolutegravir is an OCT2 and MATE1 inhibitor; however, lamivudine concentrations were similar with or without co-administration of dolutegravir based on a cross study analysis, indicating that dolutegravir has no effect on lamivudine exposure Although abacavir and lamivudine are substrates of BCRP and P-gp Established and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal products are listed in Table 1.Interactions between dolutegravir, abacavir, lamivudine and co-administered medical products are listed in Table 1 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, area under the concentration versus time curve as “AUC”, maximum observed concentration as “CEtravirine without boosted protease inhibitors / DolutegravirEtravirine without boosted protease inhibitors decreased plasma dolutegravir concentration. ‡ Includes subjects who discontinued due to an adverse event or death at any time point from Day 1 through the Week 48 analysis window if this resulted in no virologic data on treatment during the analysis window.